References
- Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366-378. https://doi.org/10.1177/2040620713489842
- Martin PJ, Inamoto Y, Flowers ME, Carpenter PA. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant. 2012;18:982-988. https://doi.org/10.1016/j.bbmt.2012.04.006
- Sellar RS, Peggs KS. Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. Future Oncol. 2012;8:1549-1565. https://doi.org/10.2217/fon.12.153
- Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy. 2009;11:503-515. https://doi.org/10.1080/14653240903193806
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586. https://doi.org/10.1016/S0140-6736(08)60690-X
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441. https://doi.org/10.1016/S0140-6736(04)16104-7
- Herrmann R, Sturm M, Shaw K, Purtill D, Cooney J, Wright M, Phillips M, Cannell P. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012;95:182-188. https://doi.org/10.1007/s12185-011-0989-2
- Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, Taniguchi S, Imamura M, Ando K, Kato S, Mori T, Teshima T, Mori M, Ozawa K. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206-213. https://doi.org/10.1007/s12185-013-1399-4
- Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559. https://doi.org/10.1371/journal.pone.0047559
- Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012;1266:107-117. https://doi.org/10.1111/j.1749-6632.2012.06667.x
- Song SU, Kim CS, Yoon SP, Kim SK, Lee MH, Kang JS, Choi GS, Moon SH, Choi MS, Cho YK, Son BK. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem Cells Dev. 2008;17:451-461. https://doi.org/10.1089/scd.2007.0167
- Lim JH, Lee MH, Yi HG, Kim CS, Kim JH, Song SU. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases. Int J Hematol. 2010;92:204-207. https://doi.org/10.1007/s12185-010-0606-9
- Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
- Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant. 2006;38:645-651. https://doi.org/10.1038/sj.bmt.1705490
- Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, Koc ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004;33:597-604. https://doi.org/10.1038/sj.bmt.1704400
- Tian Y, Deng YB, Huang YJ, Na XD, Li Y, Ye MH. Role of bone marrow-derived mesenchymal stem cells in reduction of graft-versus-host disease by effecting CD4+CD25+ regulatory T cells in rats. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14:1210-1214.
- Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582-2591. https://doi.org/10.1634/stemcells.2006-0228
Cited by
- Recipient bone marrow‐derived stromal cells prolong graft survival in a rat hind limb allotransplantation model vol.37, pp.6, 2016, https://doi.org/10.1002/micr.30128
- Interferon-γ mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro vol.23, pp.1, 2016, https://doi.org/10.1080/10245332.2017.1333245
- Transplantation of human bone marrow‐derived clonal mesenchymal stem cells reduces fibrotic scar formation in a rat spinal cord injury model vol.12, pp.2, 2016, https://doi.org/10.1002/term.2425
- Human peripheral blood-derived mesenchymal stem cells with NTRK1 over-expression enhance repairing capability in a rat model of Parkinson’s disease vol.70, pp.5, 2016, https://doi.org/10.1007/s10616-017-0175-3
- Mesenchymal stem cells and immune disorders: from basic science to clinical transition vol.13, pp.2, 2016, https://doi.org/10.1007/s11684-018-0627-y
- Infusion of Mesenchymal Stem Cells to Treat Graft Versus Host Disease: the Role of HLA-G and the Impact of its Polymorphisms vol.16, pp.3, 2016, https://doi.org/10.1007/s12015-020-09960-1